

6th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia

Learning Objectives

- Evaluate the prognostic markers, risk stratification and the impact on novel therapies for Hodgkin lymphoma
- Interpret and adapt the data from recent clinical trials on immunotherapy options for Hodgkin lymphoma
- Identify the treatment options for diffuse large B-cell lymphoma (DLBCL)
- Cite the treatment options for follicular lymphoma (FL)
- Apply the treatment options for chronic lymphocytic lymphoma (CLL)
- Identify the treatment options for mantle cell lymphoma (MCL)
- Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active multiple myeloma (MM)
- Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
- Evaluate the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with acute lymphoblastic leukemia (ALL)
- Evaluate the gene–gene co-occurrences and how compound genotypes are related to novel therapeutic options based clinical outcomes in patients with acute myeloid leukemia (AML)
- Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of chronic myelogenous leukemia (CML)
- Discuss the time-based response milestones and monitoring in patients with CML